Cardiovascular · AnticoagulantTrial Updateclinicalmid-term

Study on Rivaroxaban's Effects in Peripheral Artery Disease Initiated

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/17/2026, 6:32:20 AM

Assessment confidence: 86% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing clinical trial assessing rivaroxaban's effects on peripheral artery disease could significantly impact treatment protocols and market dynamics. Positive outcomes may bolster rivaroxaban's competitive position among anticoagulants, influencing prescribing practices and market share. Regulatory context from FDA (FDA AP — RIVAROXABAN (ORIG)) supports the near-term read. Assessment grounded in 18 ranked evidence items (16 high-relevance).

Strategic Assessment

Positive results may enhance rivaroxaban's market share in the PAD space and inform treatment guidelines. The strongest clinical anchor is The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease (ClinicalTrials.gov), entity match (rivaroxaban). In Cardiovascular · Anticoagulant, 6 regulatory and 1 competitive items passed relevance filtering for Rivaroxaban.

Competitive Pressure

The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). This study could provide insights into the efficacy of rivaroxaban, potentially influencing its competitive positioning against other anticoagulants in PAD treatment.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — RIVAROXABAN (ORIG) (FDA). Entity match (rivaroxaban); Regulatory pathway relevance (nda). The results may lead to updates in treatment guidelines and could influence future regulatory submissions or label expansions for rivaroxaban.

Key Risks

Elevated medium regulatory exposure for Rivaroxaban could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If the trial demonstrates efficacy, rivaroxaban could capture a larger share of the PAD market, potentially increasing revenue streams for its manufacturer.
Upside for Rivaroxaban may improve if A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED) (ClinicalTrials.gov) delivers favorable follow-through.
Positive results may enhance rivaroxaban's market share in the PAD space and inform treatment guidelines.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any subsequent changes in treatment recommendations for peripheral artery disease.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — RIVAROXABAN (ORIG)
FDAhigh relevance
Entity match (rivaroxaban); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — RIVAROXABAN (ORIG)
FDAhigh relevance
Entity match (rivaroxaban); Regulatory pathway relevance (nda)
FDA document
View source
Rare Disease Drug Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Rare Disease News, Events & Reports
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA Approves First At-home Starting Dose for Alzheimer’s Disease Treatment
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Learning and Education to ADvance and Empower Rare Disease Drug Developers (LEADER 3D)
FDAhigh relevance
Moderate corpus alignment
FDA document
View source

The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease
ClinicalTrials.govhigh relevance
Entity match (rivaroxaban)
FDA document
View source
A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effect of Family Participation-Based Intervention Before Coronary Artery Bypass Grafting (CABG) on Patients' Anxiety, Independence, and Psychological Resilience: A Randomized Controlled Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

Cost-effectiveness analysis of apixaban compared with other oral anticoagulants for the treatment of non-valvular atrial fibrillation in Belgian healthcare setting.
PubMedhigh relevance
Entity match (rivaroxaban)
FDA document
View source
Impact of dual antiplatelet therapy duration after percutaneous coronary intervention on outcomes in acute coronary syndrome patients with and without chronic kidney disease: a nationwide cohort study
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Effects of different caffeine doses on fat oxidation and cardiovascular response during exercise at FATmax in overweight/obese female college students.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Rivaroxaban
Peripheral Artery Disease

Commercial impact

medium

If the trial demonstrates efficacy, rivaroxaban could capture a larger share of the PAD market, potentially increasing revenue streams for its manufacturer.

Regulatory impact

medium

The results may lead to updates in treatment guidelines and could influence future regulatory submissions or label expansions for rivaroxaban.

What to watch

Monitor trial results and any subsequent changes in treatment recommendations for peripheral artery disease.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.